Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

  • Discontinued
  • GID-TA11486

NIHRIO BN: 35842-Pembrolizumab-Favezelimab-for-Hodgkin-Lymphoma-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)